AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Fang Holdings Limited
Video analysis: SFUNY
All videosNo video analysis for this stock yet. Request one from our team.
News: SFUNY
BTGO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in BitGo Holdings, Inc. Securities Lawsuit - Contact SueWallSt
Executive Accountability: Chief Revenue Officer Chen Fang Signed BitGo's Registration Statement That Allegedly Concealed the True Severity of Digital Asset Price Risks, Contributing to Investor Losses Executive Accountability: Chief Revenue Officer Chen Fang Signed BitGo's Registration Statement That Allegedly Concealed the True Severity of Digital Asset Price Risks, Contributing to Investor Losses
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.
